Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomerica (BMRA) Gains from Investment Securities (2016 - 2025)

Biomerica's Gains from Investment Securities history spans 16 years, with the latest figure at -$40000.0 for Q4 2025.

  • For Q4 2025, Gains from Investment Securities fell 1900.0% year-over-year to -$40000.0; the TTM value through Nov 2025 reached -$35000.0, up 10.26%, while the annual FY2025 figure was $413866.0, 4.85% down from the prior year.
  • Gains from Investment Securities for Q4 2025 was -$40000.0 at Biomerica, down from $3000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $1.4 million in Q1 2021 and bottomed at -$246805.0 in Q2 2022.
  • The 5-year median for Gains from Investment Securities is $19000.0 (2023), against an average of $140543.0.
  • The largest annual shift saw Gains from Investment Securities skyrocketed 118286.96% in 2021 before it tumbled 7100.0% in 2023.
  • A 5-year view of Gains from Investment Securities shows it stood at $2081.0 in 2021, then tumbled by 3655.98% to -$74000.0 in 2022, then soared by 329.73% to $170000.0 in 2023, then plummeted by 101.18% to -$2000.0 in 2024, then plummeted by 1900.0% to -$40000.0 in 2025.
  • Per Business Quant, the three most recent readings for BMRA's Gains from Investment Securities are -$40000.0 (Q4 2025), $3000.0 (Q3 2025), and $413866.0 (Q2 2025).